Alert Regarding Cisplatin-induced Severe Adverse Events in Cancer Patients with Xeroderma Pigmentosum

Xeroderma pigmentosum (XP) is a genetic disease in which DNA repair mechanisms are impaired. Cisplatin (CDDP) exerts cytotoxic effects by forming mainly intrastrand DNA cross-links, and sensitivity to CDDP depends on the DNA repair system. Several in vitro studies have suggested that treatment with...

Full description

Saved in:
Bibliographic Details
Published in:Internal Medicine 2017/04/15, Vol.56(8), pp.979-982
Main Authors: Sumiyoshi, Makoto, Soda, Hiroshi, Sadanaga, Noriaki, Taniguchi, Hirokazu, Ikeda, Takaya, Maruta, Hiroshi, Dotsu, Yosuke, Ogawara, Daiki, Fukuda, Yuichi, Mukae, Hiroshi
Format: Article
Language:English
Subjects:
Aged
Antineoplastic Agents - adverse effects
Antitumor agents
Cancer
Case Report
CDDP
Chemotherapy
Cisplatin
Cisplatin - adverse effects
Cytotoxicity
Deoxyribonucleic acid
DNA
DNA repair
DNA repair system
Fatal Outcome
Female
Humans
Internal medicine
Male
Medical personnel
multiple organ failure
Multiple Organ Failure - chemically induced
Neoplasms - drug therapy
Patients
Xeroderma Pigmentosum
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c609t-381818ed74dded9d75921f04bc6cd72214843ead46aff1037b04b3c180571613
cites cdi_FETCH-LOGICAL-c609t-381818ed74dded9d75921f04bc6cd72214843ead46aff1037b04b3c180571613
container_end_page 982
container_issue 8
container_start_page 979
container_title Internal Medicine
container_volume 56
creator Sumiyoshi, Makoto
Soda, Hiroshi
Sadanaga, Noriaki
Taniguchi, Hirokazu
Ikeda, Takaya
Maruta, Hiroshi
Dotsu, Yosuke
Ogawara, Daiki
Fukuda, Yuichi
Mukae, Hiroshi
description Xeroderma pigmentosum (XP) is a genetic disease in which DNA repair mechanisms are impaired. Cisplatin (CDDP) exerts cytotoxic effects by forming mainly intrastrand DNA cross-links, and sensitivity to CDDP depends on the DNA repair system. Several in vitro studies have suggested that treatment with CDDP may cause enhanced adverse events as well as anti-tumor activity in cancer patients with XP. This article is the first to describe two cancer patients with XP showing severe adverse events following CDDP-based chemotherapy. Physicians should pay attention when administering CDDP in cancer patients with XP.
doi_str_mv 10.2169/internalmedicine.56.7866
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5465418</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2014499785</sourcerecordid><originalsourceid>FETCH-LOGICAL-c609t-381818ed74dded9d75921f04bc6cd72214843ead46aff1037b04b3c180571613</originalsourceid><addsrcrecordid>eNptkV2LEzEUhoMobl39CxLwxpupSSaTjxuhlPUDFl10L7wLaXKmTZnJ1GSm4r83Y2vRRQLnwDnPeU-SFyFMyZJRod-EOEKKtuvBBxciLBuxlEqIR2hBa64ryermMVoQTVXFSrhCz3LeE1IrqdlTdMUUZ0Q1ZIFg1UEa8RfY2uRD3OJ1yIfOjiFWIfrJgcdf4QgJ8MqXlAHfHCGOGYeI1zY6SPiu0L9LP8K4w98gDR5Sb_Fd2PalPuSpf46etLbL8OKcr9H9u5v79Yfq9vP7j-vVbeUE0WNVK1oOeMm9B6-9bDSjLeEbJ5yXjFGueA3Wc2HblpJabkqvdlSRRlJB62v09iR7mDbla1zZnmxnDin0Nv00gw3m304MO7MdjqbhouFUFYHXZ4E0fJ8gj6YP2UHX2QjDlA1VSktJuZx3vXqA7odp9iQbRijnWkvVFEqdKJeGnBO0l8tQYmYrzUMrTSPMbGUZffn3Yy6Df7wrwKcTsM-j3cIFsGkMroP_Kqs5nDdcQLezyUCsfwHVwb5p</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2014499785</pqid></control><display><type>article</type><title>Alert Regarding Cisplatin-induced Severe Adverse Events in Cancer Patients with Xeroderma Pigmentosum</title><source>Open Access: PubMed Central</source><creator>Sumiyoshi, Makoto ; Soda, Hiroshi ; Sadanaga, Noriaki ; Taniguchi, Hirokazu ; Ikeda, Takaya ; Maruta, Hiroshi ; Dotsu, Yosuke ; Ogawara, Daiki ; Fukuda, Yuichi ; Mukae, Hiroshi</creator><creatorcontrib>Sumiyoshi, Makoto ; Soda, Hiroshi ; Sadanaga, Noriaki ; Taniguchi, Hirokazu ; Ikeda, Takaya ; Maruta, Hiroshi ; Dotsu, Yosuke ; Ogawara, Daiki ; Fukuda, Yuichi ; Mukae, Hiroshi</creatorcontrib><description>Xeroderma pigmentosum (XP) is a genetic disease in which DNA repair mechanisms are impaired. Cisplatin (CDDP) exerts cytotoxic effects by forming mainly intrastrand DNA cross-links, and sensitivity to CDDP depends on the DNA repair system. Several in vitro studies have suggested that treatment with CDDP may cause enhanced adverse events as well as anti-tumor activity in cancer patients with XP. This article is the first to describe two cancer patients with XP showing severe adverse events following CDDP-based chemotherapy. Physicians should pay attention when administering CDDP in cancer patients with XP.</description><identifier>ISSN: 0918-2918</identifier><identifier>EISSN: 1349-7235</identifier><identifier>DOI: 10.2169/internalmedicine.56.7866</identifier><identifier>PMID: 28420850</identifier><language>eng</language><publisher>Japan: The Japanese Society of Internal Medicine</publisher><subject>Aged ; Antineoplastic Agents - adverse effects ; Antitumor agents ; Cancer ; Case Report ; CDDP ; Chemotherapy ; Cisplatin ; Cisplatin - adverse effects ; Cytotoxicity ; Deoxyribonucleic acid ; DNA ; DNA repair ; DNA repair system ; Fatal Outcome ; Female ; Humans ; Internal medicine ; Male ; Medical personnel ; multiple organ failure ; Multiple Organ Failure - chemically induced ; Neoplasms - drug therapy ; Patients ; Xeroderma Pigmentosum</subject><ispartof>Internal Medicine, 2017/04/15, Vol.56(8), pp.979-982</ispartof><rights>2017 by The Japanese Society of Internal Medicine</rights><rights>Copyright Japan Science and Technology Agency 2017</rights><rights>Copyright © 2017 by The Japanese Society of Internal Medicine 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c609t-381818ed74dded9d75921f04bc6cd72214843ead46aff1037b04b3c180571613</citedby><cites>FETCH-LOGICAL-c609t-381818ed74dded9d75921f04bc6cd72214843ead46aff1037b04b3c180571613</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5465418/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5465418/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,733,786,790,891,27957,27958,53827,53829</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28420850$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sumiyoshi, Makoto</creatorcontrib><creatorcontrib>Soda, Hiroshi</creatorcontrib><creatorcontrib>Sadanaga, Noriaki</creatorcontrib><creatorcontrib>Taniguchi, Hirokazu</creatorcontrib><creatorcontrib>Ikeda, Takaya</creatorcontrib><creatorcontrib>Maruta, Hiroshi</creatorcontrib><creatorcontrib>Dotsu, Yosuke</creatorcontrib><creatorcontrib>Ogawara, Daiki</creatorcontrib><creatorcontrib>Fukuda, Yuichi</creatorcontrib><creatorcontrib>Mukae, Hiroshi</creatorcontrib><title>Alert Regarding Cisplatin-induced Severe Adverse Events in Cancer Patients with Xeroderma Pigmentosum</title><title>Internal Medicine</title><addtitle>Intern. Med.</addtitle><description>Xeroderma pigmentosum (XP) is a genetic disease in which DNA repair mechanisms are impaired. Cisplatin (CDDP) exerts cytotoxic effects by forming mainly intrastrand DNA cross-links, and sensitivity to CDDP depends on the DNA repair system. Several in vitro studies have suggested that treatment with CDDP may cause enhanced adverse events as well as anti-tumor activity in cancer patients with XP. This article is the first to describe two cancer patients with XP showing severe adverse events following CDDP-based chemotherapy. Physicians should pay attention when administering CDDP in cancer patients with XP.</description><subject>Aged</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antitumor agents</subject><subject>Cancer</subject><subject>Case Report</subject><subject>CDDP</subject><subject>Chemotherapy</subject><subject>Cisplatin</subject><subject>Cisplatin - adverse effects</subject><subject>Cytotoxicity</subject><subject>Deoxyribonucleic acid</subject><subject>DNA</subject><subject>DNA repair</subject><subject>DNA repair system</subject><subject>Fatal Outcome</subject><subject>Female</subject><subject>Humans</subject><subject>Internal medicine</subject><subject>Male</subject><subject>Medical personnel</subject><subject>multiple organ failure</subject><subject>Multiple Organ Failure - chemically induced</subject><subject>Neoplasms - drug therapy</subject><subject>Patients</subject><subject>Xeroderma Pigmentosum</subject><issn>0918-2918</issn><issn>1349-7235</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNptkV2LEzEUhoMobl39CxLwxpupSSaTjxuhlPUDFl10L7wLaXKmTZnJ1GSm4r83Y2vRRQLnwDnPeU-SFyFMyZJRod-EOEKKtuvBBxciLBuxlEqIR2hBa64ryermMVoQTVXFSrhCz3LeE1IrqdlTdMUUZ0Q1ZIFg1UEa8RfY2uRD3OJ1yIfOjiFWIfrJgcdf4QgJ8MqXlAHfHCGOGYeI1zY6SPiu0L9LP8K4w98gDR5Sb_Fd2PalPuSpf46etLbL8OKcr9H9u5v79Yfq9vP7j-vVbeUE0WNVK1oOeMm9B6-9bDSjLeEbJ5yXjFGueA3Wc2HblpJabkqvdlSRRlJB62v09iR7mDbla1zZnmxnDin0Nv00gw3m304MO7MdjqbhouFUFYHXZ4E0fJ8gj6YP2UHX2QjDlA1VSktJuZx3vXqA7odp9iQbRijnWkvVFEqdKJeGnBO0l8tQYmYrzUMrTSPMbGUZffn3Yy6Df7wrwKcTsM-j3cIFsGkMroP_Kqs5nDdcQLezyUCsfwHVwb5p</recordid><startdate>20170101</startdate><enddate>20170101</enddate><creator>Sumiyoshi, Makoto</creator><creator>Soda, Hiroshi</creator><creator>Sadanaga, Noriaki</creator><creator>Taniguchi, Hirokazu</creator><creator>Ikeda, Takaya</creator><creator>Maruta, Hiroshi</creator><creator>Dotsu, Yosuke</creator><creator>Ogawara, Daiki</creator><creator>Fukuda, Yuichi</creator><creator>Mukae, Hiroshi</creator><general>The Japanese Society of Internal Medicine</general><general>Japan Science and Technology Agency</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20170101</creationdate><title>Alert Regarding Cisplatin-induced Severe Adverse Events in Cancer Patients with Xeroderma Pigmentosum</title><author>Sumiyoshi, Makoto ; Soda, Hiroshi ; Sadanaga, Noriaki ; Taniguchi, Hirokazu ; Ikeda, Takaya ; Maruta, Hiroshi ; Dotsu, Yosuke ; Ogawara, Daiki ; Fukuda, Yuichi ; Mukae, Hiroshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c609t-381818ed74dded9d75921f04bc6cd72214843ead46aff1037b04b3c180571613</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Aged</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antitumor agents</topic><topic>Cancer</topic><topic>Case Report</topic><topic>CDDP</topic><topic>Chemotherapy</topic><topic>Cisplatin</topic><topic>Cisplatin - adverse effects</topic><topic>Cytotoxicity</topic><topic>Deoxyribonucleic acid</topic><topic>DNA</topic><topic>DNA repair</topic><topic>DNA repair system</topic><topic>Fatal Outcome</topic><topic>Female</topic><topic>Humans</topic><topic>Internal medicine</topic><topic>Male</topic><topic>Medical personnel</topic><topic>multiple organ failure</topic><topic>Multiple Organ Failure - chemically induced</topic><topic>Neoplasms - drug therapy</topic><topic>Patients</topic><topic>Xeroderma Pigmentosum</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sumiyoshi, Makoto</creatorcontrib><creatorcontrib>Soda, Hiroshi</creatorcontrib><creatorcontrib>Sadanaga, Noriaki</creatorcontrib><creatorcontrib>Taniguchi, Hirokazu</creatorcontrib><creatorcontrib>Ikeda, Takaya</creatorcontrib><creatorcontrib>Maruta, Hiroshi</creatorcontrib><creatorcontrib>Dotsu, Yosuke</creatorcontrib><creatorcontrib>Ogawara, Daiki</creatorcontrib><creatorcontrib>Fukuda, Yuichi</creatorcontrib><creatorcontrib>Mukae, Hiroshi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Internal Medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sumiyoshi, Makoto</au><au>Soda, Hiroshi</au><au>Sadanaga, Noriaki</au><au>Taniguchi, Hirokazu</au><au>Ikeda, Takaya</au><au>Maruta, Hiroshi</au><au>Dotsu, Yosuke</au><au>Ogawara, Daiki</au><au>Fukuda, Yuichi</au><au>Mukae, Hiroshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Alert Regarding Cisplatin-induced Severe Adverse Events in Cancer Patients with Xeroderma Pigmentosum</atitle><jtitle>Internal Medicine</jtitle><addtitle>Intern. Med.</addtitle><date>2017-01-01</date><risdate>2017</risdate><volume>56</volume><issue>8</issue><spage>979</spage><epage>982</epage><pages>979-982</pages><issn>0918-2918</issn><eissn>1349-7235</eissn><notes>ObjectType-Case Study-2</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-4</notes><notes>content type line 23</notes><notes>ObjectType-Report-1</notes><notes>ObjectType-Article-3</notes><notes>Correspondence to Dr.　Hiroshi Soda, h-souda@hospital.sasebo.nagasaki.jp</notes><abstract>Xeroderma pigmentosum (XP) is a genetic disease in which DNA repair mechanisms are impaired. Cisplatin (CDDP) exerts cytotoxic effects by forming mainly intrastrand DNA cross-links, and sensitivity to CDDP depends on the DNA repair system. Several in vitro studies have suggested that treatment with CDDP may cause enhanced adverse events as well as anti-tumor activity in cancer patients with XP. This article is the first to describe two cancer patients with XP showing severe adverse events following CDDP-based chemotherapy. Physicians should pay attention when administering CDDP in cancer patients with XP.</abstract><cop>Japan</cop><pub>The Japanese Society of Internal Medicine</pub><pmid>28420850</pmid><doi>10.2169/internalmedicine.56.7866</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0918-2918
ispartof Internal Medicine, 2017/04/15, Vol.56(8), pp.979-982
issn 0918-2918
1349-7235
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5465418
source Open Access: PubMed Central
subjects Aged
Antineoplastic Agents - adverse effects
Antitumor agents
Cancer
Case Report
CDDP
Chemotherapy
Cisplatin
Cisplatin - adverse effects
Cytotoxicity
Deoxyribonucleic acid
DNA
DNA repair
DNA repair system
Fatal Outcome
Female
Humans
Internal medicine
Male
Medical personnel
multiple organ failure
Multiple Organ Failure - chemically induced
Neoplasms - drug therapy
Patients
Xeroderma Pigmentosum
title Alert Regarding Cisplatin-induced Severe Adverse Events in Cancer Patients with Xeroderma Pigmentosum
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-22T09%3A20%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Alert%20Regarding%20Cisplatin-induced%20Severe%20Adverse%20Events%20in%20Cancer%20Patients%20with%20Xeroderma%20Pigmentosum&rft.jtitle=Internal%20Medicine&rft.au=Sumiyoshi,%20Makoto&rft.date=2017-01-01&rft.volume=56&rft.issue=8&rft.spage=979&rft.epage=982&rft.pages=979-982&rft.issn=0918-2918&rft.eissn=1349-7235&rft_id=info:doi/10.2169/internalmedicine.56.7866&rft_dat=%3Cproquest_pubme%3E2014499785%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c609t-381818ed74dded9d75921f04bc6cd72214843ead46aff1037b04b3c180571613%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2014499785&rft_id=info:pmid/28420850&rfr_iscdi=true